Curing Lupus Atlas

Gold-standard evidence hub

The gut microbiome and lupus

Human associations and animal experiments support a disease-modifier model; clinical intervention evidence remains preliminary.

Inspect claimsRead the method

One-minute summary

  • Case-control studies find differences in gut diversity and composition between SLE groups and controls.
  • R. gnavus expansion and strain-specific antibody responses have been associated with disease activity and lupus nephritis.
  • Animal transfer studies support biological effects, but mice do not establish causality in people.
  • A 20-person uncontrolled FMT pilot reported SRI-4 responses; no comparator means efficacy remains unknown.

What we still do not know

  • Which microbiome changes precede disease rather than follow inflammation, diet, geography, or medication
  • Whether any individual microbe has a clinically important causal effect in a defined SLE subgroup
  • Whether FMT, probiotics, or diet improves patient-important outcomes in adequately controlled trials
  • How to define a safe, reproducible microbiome intervention in immunosuppressed people
  • Whether microbiome manipulation changes outcomes after CAR-T or other B-cell depletion

Safety boundary

FMT and live-microbe products can transmit infection and are not established SLE treatments. The site does not provide organism, donor, dose, or timing instructions.

Claim-level evidence

What each source supports—and what it does not

Every card distinguishes patient outcomes, human mechanisms, models, and site inference.

What human studies observe

Diversity, composition, and disease-associated microbial immune responses.

Observational associationVerified 2026-07-10

SLE is associated with altered gut microbial diversity and composition

Across several studies, people with lupus had differences in gut microbial diversity and some bacterial groups compared with healthy controls. Medicines and active disease can also change the microbiome, so the direction of cause is unclear.

Evidence design
Systematic Review + Case Control
Directness
Human Mechanism
Inspect the evidence

Technical interpretation

A meta-analysis of 11 case-control studies found lower Shannon diversity and Chao1 richness in SLE. Taxonomic signals were less uniform, and treatment exposure is an important confounder.

Evidence and provenance

Limitations

  • Geography, diet, sequencing pipeline, medication, and disease activity can affect results
  • Associations do not distinguish cause from consequence
  • Individual taxa findings are not fully consistent across studies

Review state: Citation Audited · Record ID: microbiome-dysbiosis-association

Observational associationVerified 2026-07-10

Ruminococcus gnavus expansion and strain-specific immunity correlate with active lupus nephritis

One human study found more R. gnavus in lupus and stronger antibody responses to particular strains in people with active kidney disease. This is a lead to investigate, not proof that the bacterium caused nephritis.

Evidence design
Case Control
Directness
Human Mechanism
Inspect the evidence

Technical interpretation

Azzouz et al. reported approximately fivefold greater overall R. gnavus representation in SLE and associations among strain-restricted anti-R. gnavus lipoglycan antibodies, disease activity, anti-native DNA, complement, and active nephritis.

Evidence and provenance

Limitations

  • The antibody response was not uniform across R. gnavus strains
  • Temporal direction and causal effect are unresolved
  • Do not translate this association into antimicrobial or probiotic self-treatment advice

Review state: Citation Audited · Record ID: microbiome-r-gnavus-nephritis

What experiments add

Preclinical transfer evidence and its translation boundary.

Preclinical evidenceVerified 2026-07-10

Microbiota transfer can modify lupus-like immune features in mice

Moving gut microbes from lupus-prone mice into germ-free mice increased some lupus-related immune signals. That supports biological plausibility but does not tell us whether a microbiome treatment helps people.

Evidence design
Animal Model
Directness
Model Organism
Inspect the evidence

Technical interpretation

A preclinical FMT experiment reported that microbiota from lupus-prone mice increased anti-dsDNA antibodies and altered immune-cell and gene-expression measures in germ-free recipients.

Evidence and provenance

Limitations

  • Mouse transfer experiments do not establish causality or therapeutic benefit in human SLE
  • Results depend strongly on host genetics, housing, diet, and donor community

Review state: Citation Audited · Record ID: microbiome-preclinical-transfer

Unsupported / contradictedVerified 2026-07-10

Current evidence does not show that a specific microbiome is required to initiate SLE

The microbiome may influence disease activity, but the evidence does not support calling it the single cause or an essential driver in every person with lupus.

Evidence design
Systematic Review + Animal Model
Directness
Inference
Inspect the evidence

Technical interpretation

Human evidence is predominantly observational, while transfer evidence is preclinical. Together these support a modifier or contributor model more strongly than a universal initiating mechanism.

Evidence and provenance

Limitations

  • This conclusion does not exclude important causal effects for particular microbes or patient subgroups

Review state: Citation Audited · Record ID: microbiome-not-required

What has been tried

An uncontrolled FMT pilot and untested combination ideas.

Emerging / preliminaryVerified 2026-07-10

A small uncontrolled FMT pilot reported SRI-4 responses

In a 20-person pilot, 42.12% met a trial response measure after oral donor-microbiota capsules plus their usual stable treatment. Without a control group, we cannot know how much of that change came from FMT.

Evidence design
Nonrandomized Interventional
Directness
Clinical Outcome
Inspect the evidence

Technical interpretation

The EXPLORER single-arm pilot administered encapsulated FMT weekly for three weeks to 20 people with active SLE. At week 12, 42.12% met SRI-4, with changes in disease activity, anti-dsDNA, microbial composition, metabolites, and immune measures. It was a feasibility signal, not a comparative efficacy estimate.

Evidence and provenance

Limitations

  • No placebo or concurrent control
  • Only 20 participants and 12 weeks
  • Participants continued stable background treatment
  • The article has an erratum; exact reuse should be checked against the corrected record
  • FMT has infection and transmission risks and is not established SLE care

Review state: Citation Audited · Record ID: microbiome-fmt-pilot

Site hypothesisVerified 2026-07-10

Microbiome treatment after CAR-T is an untested combination

No cited study shows that FMT, probiotics, or a selected bacterial mix makes CAR-T safer or more durable in lupus.

Evidence design
Case Series + Nonrandomized Interventional + Animal Model
Directness
Inference
Inspect the evidence

Technical interpretation

Combining microbiome manipulation with B-cell reconstitution after CAR-T is a mechanistic hypothesis. The source set contains neither a post-CAR-T intervention study nor validated organisms, doses, timing, or safety criteria for such a combination.

Evidence and provenance

Limitations

  • Potential infection risk may be especially relevant after lymphodepletion
  • Specific probiotic organisms should not be represented as a protocol without clinical evidence

Review state: Citation Audited · Record ID: microbiome-adjunct-unproven